Aguilar Elisabet, Bagó Julio Rodriguez, Soler-Botija Carol, Alieva Maria, Rigola Maria Angeles, Fuster Carme, Vila Olaia F, Rubio Nuria, Blanco Jeronimo
1 Human DNA Variability Department, GENYO-Centre for Genomic and Oncological Research (Pfizer/University of Granada/Andalusian Regional Government) , PTS Granada, Granada, Spain .
Stem Cells Dev. 2014 Dec 1;23(23):2908-20. doi: 10.1089/scd.2014.0231. Epub 2014 Aug 13.
Human mesenchymal stromal cells, whether from the bone marrow or adipose tissue (hASCs), are promising cell therapy agents. However, generation of abundant cells for therapy remains to be a challenge, due to the need of lengthy expansion and the risk of accumulating genomic defects during the process. We show that hASCs can be easily induced to a reversible fast-proliferating phenotype (FP-ASCs) that allows rapid generation of a clinically useful quantity of cells in <2 weeks of culture. Expanded FP-ASCs retain their finite expansion capacity and pluripotent properties. Despite the high proliferation rate, FP-ASCs show genomic stability by array-comparative genomic hybridization, and did not generate tumors when implanted for a long time in an SCID mouse model. Comparative analysis of gene expression patterns revealed a set of genes that can be used to characterize FP-ASCs and distinguish them from hASCs. As potential candidate therapeutic agents, FP-ASCs displayed high vasculogenic capacity in Matrigel assays. Moreover, application of hASCs and FP-ASCs in a fibrin scaffold over a myocardium infarct model in SCID mice showed that both cell types can differentiate to endothelial and myocardium lineages, although FP-ASCs were more potent angiogenesis inducers than hASCs, at promoting myocardium revascularization.
人骨髓间充质干细胞以及脂肪组织来源的人间充质干细胞(hASC)都是很有前景的细胞治疗制剂。然而,由于需要长时间的扩增以及在此过程中积累基因组缺陷的风险,为治疗生成大量细胞仍然是一个挑战。我们发现,hASC可以很容易地被诱导成一种可逆的快速增殖表型(FP-ASC),这种表型能够在不到2周的培养时间内快速生成临床上可用数量的细胞。扩增后的FP-ASC保留了其有限的扩增能力和多能特性。尽管增殖率很高,但通过阵列比较基因组杂交分析,FP-ASC显示出基因组稳定性,并且在SCID小鼠模型中长期植入时不会产生肿瘤。基因表达模式的比较分析揭示了一组可用于表征FP-ASC并将其与hASC区分开来的基因。作为潜在的候选治疗制剂,FP-ASC在基质胶试验中显示出高血管生成能力。此外,在SCID小鼠心肌梗死模型的纤维蛋白支架中应用hASC和FP-ASC表明,尽管在促进心肌血管再生方面,FP-ASC比hASC是更强的血管生成诱导剂,但两种细胞类型都可以分化为内皮细胞和心肌细胞谱系。